大缺血区域急性卒中的血管内治疗
该研究为日本多中心、开放标签、随机临床试验,纳入大血管闭塞且影像显示大梗死核心(ASPECTS 3~5)的患者,随机接受血管内治疗加内科治疗或单纯内科治疗,两组均酌情使用阿替普酶0.6 mg/kg。主要终点90天改良Rankin量表评分0~3分比例,血管内治疗组31.0% vs 内科治疗组12.7%(RR 2.43,95%CI 1.35~4.37,P=0.002)。48小时NIHSS评分改善≥8分比例31.0% vs 8.8%(RR 3.51,95%CI 1.76~7.00),任何颅内出血58.0% vs 31.4%(P<0.001)。结论为大梗死患者血管内治疗功能结局更好,但颅内出血更多。
要点
- 大梗死核心(ASPECTS 3~5)急性卒中患者,90天mRS 0~3分比例血管内治疗组31.0% vs 内科治疗组12.7%(RR 2.43,95%CI 1.35~4.37,P=0.002)。
- 48小时NIHSS评分改善≥8分比例血管内治疗组31.0% vs 内科治疗组8.8%(RR 3.51,95%CI 1.76~7.00)。
- 任何颅内出血发生率血管内治疗组58.0% vs 内科治疗组31.4%(P<0.001)。
- 两组约27%患者接受阿替普酶0.6 mg/kg治疗。
- 研究在日本进行,纳入大血管闭塞且影像显示大梗死核心(ASPECTS 3~5)的患者。
适用人群与场景
- 日本多中心研究纳入大血管闭塞且影像显示大梗死核心(ASPECTS 3~5)的急性缺血性卒中患者。
- 患者在最后已知正常后6小时内随机,或若液体衰减反转恢复序列无早期改变则在24小时内随机。
诊断标准与关键阈值
- 大梗死核心定义为Alberta卒中项目早期CT评分(ASPECTS)3~5分(量表0~10分,分值越低提示梗死越大)。
- 主要终点为90天改良Rankin量表评分0~3分(量表0~6分,分值越高残疾越重)。
- 次要终点包括90天改良Rankin量表评分沿全范围向更好结局的移位,以及48小时美国国立卫生研究院卒中量表(NIHSS)评分(范围0~42分,分值越高缺损越重)改善至少8分。
处置流程与药物剂量
- 随机1:1分配至血管内治疗加内科治疗组或单纯内科治疗组。
- 两组均在适当时使用阿替普酶0.6 mg/kg体重。
红旗征与不能漏的情况
- 任何颅内出血发生率血管内治疗组58.0% vs 内科治疗组31.4%(P<0.001)。
研究设计与关键结果
- 多中心、开放标签、随机临床试验,共203例患者随机,血管内治疗组101例,内科治疗组102例。
- 两组约27%患者接受阿替普酶治疗。
- 90天改良Rankin量表评分0~3分比例血管内治疗组31.0% vs 内科治疗组12.7%(相对危险度2.43;95%CI 1.35~4.37;P=0.002)。
- 改良Rankin量表评分沿全范围的有序移位总体 favoring 血管内治疗。
- 48小时NIHSS评分改善至少8分比例血管内治疗组31.0% vs 内科治疗组8.8%(相对危险度3.51;95%CI 1.76~7.00)。
- 任何颅内出血发生率血管内治疗组58.0% vs 内科治疗组31.4%(P<0.001)。
证据类型、等级与局限
- 多中心、开放标签、随机临床试验(RESCUE-Japan LIMIT,ClinicalTrials.gov NCT03702413)。
- 由Mihara脑血管疾病研究促进基金和日本神经血管内治疗学会资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于大血管闭塞且ASPECTS 3~5的大梗死核心急性卒中患者,血管内治疗加内科治疗较单纯内科治疗提高90天功能独立比例,但颅内出血更多。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Endovascular therapy for acute ischemic stroke is generally avoided when the infarction is large, but the effect of endovascular therapy with medical care as compared with medical care alone for large strokes has not been well studied.
METHODS: We conducted a multicenter, open-label, randomized clinical trial in Japan involving patients with occlusion of large cerebral vessels and sizable strokes on imaging, as indicated by an Alberta Stroke Program Early Computed Tomographic Score (ASPECTS) value of 3 to 5 (on a scale from 0 to 10, with lower values indicating larger infarction). Patients were randomly assigned in a 1:1 ratio to receive endovascular therapy with medical care or medical care alone within 6 hours after they were last known to be well or within 24 hours if there was no early change on fluid-attenuated inversion recovery images. Alteplase (0.6 mg per kilogram of body weight) was used when appropriate in both groups. The primary outcome was a modified Rankin scale score of 0 to 3 (on a scale from 0 to 6, with higher scores indicating greater disability) at 90 days. Secondary outcomes included a shift across the range of modified Rankin scale scores toward a better outcome at 90 days and an improvement of at least 8 points in the National Institutes of Health Stroke Scale (NIHSS) score (range, 0 to 42, with higher scores indicating greater deficit) at 48 hours.
RESULTS: A total of 203 patients underwent randomization; 101 patients were assigned to the endovascular-therapy group and 102 to the medical-care group. Approximately 27% of patients in each group received alteplase. The percentage of patients with a modified Rankin scale score of 0 to 3 at 90 days was 31.0% in the endovascular-therapy group and 12.7% in the medical-care group (relative risk, 2.43; 95% confidence interval [CI], 1.35 to 4.37; P = 0.002). The ordinal shift across the range of modified Rankin scale scores generally favored endovascular therapy. An improvement of at least 8 points on the NIHSS score at 48 hours was observed in 31.0% of the patients in the endovascular-therapy group and 8.8% of those in the medical-care group (relative risk, 3.51; 95% CI, 1.76 to 7.00), and any intracranial hemorrhage occurred in 58.0% and 31.4%, respectively (P<0.001).
CONCLUSIONS: In a trial conducted in Japan, patients with large cerebral infarctions had better functional outcomes with endovascular therapy than with medical care alone but had more intracranial hemorrhages. (Funded by Mihara Cerebrovascular Disorder Research Promotion Fund and the Japanese Society for Neuroendovascular Therapy; RESCUE-Japan LIMIT ClinicalTrials.gov number, NCT03702413.).
参考来源
- Yoshimura S, Sakai N, Yamagami H, et al. Endovascular Therapy for Acute Stroke with a Large Ischemic Region. N Engl J Med. 2022. PMID: 35138767. doi:10.1056/NEJMoa2118191
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。